Icon
+91 94997 68112
Login Register

Bosulif - (100,500 mg; Tablet, Oral)

Bosutinib Pfizer
100,500 mg; Tablet, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
Less Than 5
None None
Indicated for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy.
Yes
*** ****** *** ******* *** *** ***** ** **** **** ** **** ******* '*** *** **, ****, '*** *** **, **** *** **** ************ *********. ** ****** **** **** *** **** ****** ** *** ****. ***** *** *** ***** **** ** **** '*** (*** **, ****) ** ****** *** *********. *** *** ********* **** ***** **** *** **** *** ***** ****** ********* (*** **, ****). ***** *** ******* ****** ** ********* ** ****** *** ******* ****** ****** ** ******** ****** *** ****. ******* **** ******* ******* *** ****** '*** *** ***** ****** ***** ***-************ ** *** ******. *** ****** *** ********* ******** ****** ********** ** ** ****** ****. ********* *** ****** ** ******** *** *** **** ***********. ***-*** *********** **** ****** ** ******** **, ****. *********, ***** ******** ** *** ****** ****** ** ******* ***** *** ***-*** *********** *** *******, ********* ******** **, ****. ********** ******* **** *******. ******* **** ****** ******* ***** *** **** ***********. *****, ********** ******* **** *** ****** *** *** ****.
Bosulif Patent 1 Patent 2 Patent 3 Patent 4
******* ******* ******* ******* **** ***
*** ****** ******* ******* ******* **** ***
*** **** ******* ******* ******* **** ***
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ ** **** **, **** ******* **** ***** *** **** ***********
*** ****** *** \ *** **** **, **** ******* ********* ******** ***** *** **, **** (*.* ****** ** ***-*** ***********)
*** **** ** \ ** **** *, **** ******* ********* ******** ***** *** **** ***********
  1. *** *, **** : ******* ******** ***** ***** *** **** ** **** ******* '*** *** **, ****, '*** *** **, ****
  2. *** **, **** : *** ****** ******** ***** ***** *** **** ** **** ******* '*** *** **, ****, '*** *** **, ****
  3. *** **, **** : ****** (*****) ***** * **** ******* ******* *** ***.
  4. *** **, **** : *** ******** ***** ***** *** **** ** **** ****** '*** (*** **, ****).
  5. *** *, **** : ***** **** *** ** ** ** ********.
  6. *** **, **** : ********** ********* **** *** ****
  7. *** **, **** : ******* **** *** ******* ******* *** ****** '***.
  8. *** **, **** : *** ****** *** ********* ********. *****://***.**********.***.***/**********_****/*********/****/*****************_***.***
  9. *** *, **** : ***** ******* **** *******, ***** *** ***** ** ********** *** *** *****.
  10. *** *, **** : ***** ******* **** *** ******, ***** *** ***** ** ********** *** *** *****.

Bosulif - (400 mg, tablet, oral)

Bosutinib Pfizer
400 mg, tablet, oral
Less Than $1000 mn
None None
Less Than 5
 None
None None
Indicated for the treatment of adult patients with newly-diagnosed chronic phase Ph+ chronic myelogenous leukemia (CML) as well as for chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy.
Yes
******* **** ** *****. *** ********* ***.
Bosulif Patent 1 Patent 2 Patent 3 Patent 4
** *******
  1. *** **, **** : * **** ** ** ***** *** ******* ** ******* *** *******

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.